In the study of Moon et al. 30, using arginase inhibitor nor-NOHA that is an isoform non-specific inhibitor, the authors showed some similar findings to the ones we obtained with Arg-II−/− mice including reduced liver steatosis and liver triglyceride content, reduced expression of SCD-1 as well as elevated AMPK signaling. The gene discussed is SCD; the disease is fatty liver disease.